Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients

Cardiology

Volumn 114, Issue 1, 2009, Pages 32-38

  Matsumoto, Yoshihiro ^a,g   Kageyama, Shinji ^b   Yakushigawa, Toru ^c   Arihara, Kazuo ^d   Sugiyama, Toshikazu ^e   Mori, Yasuo ^c   Sugiyama, Hatsumi ^e   Ohmura, Hiromichi ^f   Shio, Nobuo ^b  

^a SHIZUOKA CITY SHIMIZU HOSPITAL   (Japan)

^b Shio Urologic Clinic   (Japan)

^c Shibukawa Clinic   (Japan)

^d Ohtemachi Clinic   (Japan)

^e Sugiyama Veterinary Clinic   (Japan)

^f Sugawara Clinic   (Japan)

^g NONE   (Japan)

Author keywords

Cardiovascular risk; Hemodialysis; Hyperkalemia; Spironolactone

Indexed keywords

POTASSIUM; SPIRONOLACTONE;

ADULT; AGED; ANURIA; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GYNECOMASTIA; HEART FAILURE; HEART PROTECTION; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OLIGURIA; PARESTHESIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; UNPLEASANT SENSATION;

AGED; AGED, 80 AND OVER; ALDOSTERONE ANTAGONISTS; FEMALE; HUMANS; HYPERKALEMIA; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POTASSIUM; RENAL DIALYSIS; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 63349097399     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000210553     Document Type: Article

References (23)

1. Takeda Y, Yoneda T, Demura M, Furukawa K, Miyamori I, Mabuchi H: Effects of high sodium intake on cardiovascular aldoste-rone synthesis in stroke-prone spontaneously hypertensive rats. J Hypertens 2001;19: 635-639.
2. Takeda Y: Vascular synthesis of aldosterone: role in hypertension. Mol Cell Endocrinol 2004;31:75-79.
3. Schäfer A, Fraccarollo D, Hildemann SK, Tas P, Er t l G, Bauersachs J: Addition of the selective aldosterone receptor antagonist eplere-none to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res 2003;58:655-662.
4. Schohn DC, Jahn HA, Pelletier BC: Dose-related cardiovascular effects of spironolac-tone. Am J Cardiol 1993;71:40A-45A.
5. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-1865.
6. Sun Y, Ramires FJ, Weber KT: Fibrosis of atria and great vessels in response to angio-tensin II or aldosterone infusion. Cardiovasc Res 1997;35:138-147.
7. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341: 709-717.
8. United States Renal Data System: Annual Data Report. VI. Causes of death. Am J Kidney Dis 1999;34:S87-S94.
9. Marcelli D, Stannard D, Conte F, Held PJ, Locatelli F, Port FK: ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int 1996;50:1013-1018.
10. Hussain S, Dreyfus DE, Marcus RJ, Biederman RW, McGill RL: Is spironolactone safe for dialysis patients? Nephrol Dial Transplant 2003;18:2364-2368.
11. Vlassopoulos D, Sonikian M, Dardioti V, Pani I, Hadjilouka-Mantaka A, Hadjiconstantinou V: Insulin and mineralocorticoids influence on extrarenal potassium metabolism in chronic hemodialysis patients. Ren Fail 2001;23:833-842.
12. Sugarman A, Brown RS: The role of aldosterone in potassium tolerance: studies in anephric humans. Kidney Int 1988;34:397-403.
13. Saudan P, Mach F, Perneger T, Schnetzler B, Stoermann C, Fumeaux Z, Rossier M, Martin PY: Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 2003;18: 2359-2363.
14. Gross E, Rothstein M, Dombek S, Juknis HI: Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 2005;46:94-101.
15. Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO: Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002;105:2231-2239.
16. Struthers AD, MacDonald TM: Review of al-dosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004;61:663-670.
17. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E: Selective aldosterone blockade prevents angiotensin II/ salt-induced vascular inflammation in the rat heart. Endocrinolog y 2002;143:4828-4836.
18. Feria I, Pichardo I, Juárez P, Ramírez V, González MA, Uribe N, García-Torres R, López-Casillas F, Gamba G, Bobadilla NA: Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephro-toxicity. Kidney Int 2003;63:43-52.
19. Yalcin AI, Dincer M, Aslan V, Gulbas Z: Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res 2002;25:260-264.
20. Frohnert PP, Giuliani ER, Friedberg M, Johnson WJ, Tauxe WN: Statistical investigation of correlations between serum potassium levels and electrocardiographic findings in patients on intermittent hemodialysis therapy. Circulation 1970;41:667-676.
21. Papadimitriou M, Roy RR, Varkarakis M: Electrocardiographic changes and plasma potassium levels in patients on regular hae-modialysis. Br Med J 1970;2:268-269.
22. Szerlip HM, Weiss J, Singer I: Profound hyperkalemia without electrocardiographic manifestations. Am J Kidney Dis 1986;7: 461-465.
23. Ravis WR, Reid S, Sica DA, Tolbert DS: Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol 2005;45: 810-821.